Supreme Court Allows Telehealth and Mail Access to Abortion Pill Mifepristone
The Supreme Court allowed women to continue accessing the abortion pill mifepristone through telehealth visits on Thursday, maintaining the status quo while Louisiana pushes for limiting availability.
Objective Facts
The Supreme Court on Thursday allowed women to continue to access the abortion pill mifepristone through telehealth visits, maintaining the status quo while officials in Louisiana continue to push for limiting availability of the drug in lower courts. The conservative Supreme Court imposed a pause on a May 1 decision from the 5th US Circuit Court of Appeals that abruptly required women to obtain the drug through in-person visits. The FDA's 2023 modification of the mifepristone REMS eliminated a longstanding requirement that the drug be dispensed during an in-person medical visit and allowed for telehealth prescribing, mail delivery, and dispensing through retail pharmacies. Louisiana, which prohibits nearly all abortions, sued the FDA in October 2025, arguing that the rule change was arbitrary and capricious under the Administrative Procedure Act and that the mailing of the drug violates the Comstock Act. The court did not explain its reasoning, nor did it disclose the vote count.
Left-Leaning Perspective
Abortion-rights advocates welcomed the decision. Alexis McGill Johnson, president of the Planned Parenthood Action Fund, said in a statement 'The Supreme Court just did the bare minimum, but this ruling is a relief for patients who can continue to get the care they need. We know this is just one in a long line of attacks on our rights and our care.' Nancy Northup, president and CEO of the Center for Reproductive Rights, emphasized that 'This isn't a matter of convenience — for patients living hundreds of miles from the nearest clinic, it's the difference between getting an abortion or not' and noted that the order 'buys time, but no peace of mind.' Senate Minority Leader Charles E. Schumer said 'Today's order preserves access for the time being, but it does not change the fact that safe access to abortions and reproductive health care remains under attack.' Nearly two dozen Democratic-led states submitted an amicus brief arguing that the appeals court decision put the policy choices of states with bans above the choices of states 'that have made the different but equally sovereign determinations to promote access to abortion care.' Left-leaning outlets emphasized that the ruling was temporary and preliminary, not a final victory. Democrats made clear they will still try to use abortion as a political issue, just as they did in the 2022 election, after Roe was overturned. Left-leaning coverage focused on the accessibility angle—highlighting that mail access to mifepristone is critical for patients in states with abortion bans. What left-leaning voices largely downplayed was the genuine constitutional tension in the case regarding federal-state dynamics and the question of whether the Supreme Court itself should hear the full merits of Louisiana's challenge on the regular docket.
Right-Leaning Perspective
Louisiana Attorney General Liz Murrill said 'It's shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight' and stated 'DOJ did not defend Big Pharma, which is profiting from the illegal and unethical distribution of abortion pills.' Justice Alito, in dissent, wrote 'What is at stake is the perpetration of a scheme to undermine our decision' overturning constitutional abortion rights. John Seago, who heads the Texas-based anti-abortion group Texas Right to Life, said the Trump administration could intervene, directing the FDA to reverse its decision approving telehealth distribution of mifepristone. Gavin Oxley, a spokesperson for Americans United for Life, said the decision is 'extremely disappointing' but not a defeat, stating 'The Supreme Court still has the opportunity to hear the case in full and bring justice to Louisiana.' Anti-abortion groups, frustrated with President Donald Trump's administration, are pushing the FDA to move faster with a review that they hope will result in restrictions on mifepristone, including blocking its prescribing via telehealth platforms. Right-leaning coverage focused on safety concerns and the idea that pill-by-mail access undermines state sovereignty, particularly Louisiana's abortion ban. The right emphasized that mifepristone is flooding into Louisiana despite its ban, and that the Supreme Court majority was "unreasoned" in its decision. What right-leaning voices did not emphasize was the finding by major medical associations that adverse events from mifepristone occur in less than 0.32% of patients, or that data show the drug is safer than penicillin or Viagra.
Deep Dive
The Supreme Court's May 14 order preserving mail and telehealth access to mifepristone represents a collision between three competing frameworks: the FDA's authority to regulate drugs based on scientific evidence, states' rights to restrict abortion following Dobbs, and individual access to legal medication abortion across state lines. On May 1, a three-judge panel of the Fifth Circuit granted Louisiana's request to suspend the 2023 REMS while the appeal proceeds, effectively reinstating the in-person dispensing requirement nationwide. Danco Laboratories, the maker of mifepristone, raced up to the Supreme Court on May 2 with an emergency appeal, warning of the chaos. The Supreme Court's unsigned stay was technically a minimal order—maintaining status quo pending full briefing and decision by the Fifth Circuit—yet it signaled that at least five justices (the minimum needed) were unwilling to let a nationwide in-person requirement take effect immediately. The stay will remain in effect through the Fifth Circuit's disposition of the underlying appeal and any subsequent petition for a writ of certiorari. Should the court deny review, the stay terminates automatically. What each side sees in this differently is instructive: Abortion-rights advocates note that mifepristone has become essential to abortion access since Dobbs (roughly 25% of all abortions in 2025), while anti-abortion advocates note that Louisiana reports over 1,000 medication abortions monthly despite its near-total ban, arguing this demonstrates how mail access directly undermines state sovereignty. The FDA's 2023 regulatory decision itself remains contested on administrative law grounds, with Louisiana arguing it was arbitrary and capricious. Notably, the Trump administration's dynamic of defending the FDA rule on mifepristone has put it in the unusual position of being on the outs with anti-abortion groups, and although the agency has said nothing, allowing a deadline to submit a brief pass without comment. The Louisiana case will continue to make its way through the courts, and could ultimately end up argued before the Supreme Court. The outcome will likely depend on whether the Court decides to hear the case on full merits and, if so, whether a majority views post-Dobbs federalism as requiring strict state sovereignty over abortion regulation (favoring Louisiana) or maintains that FDA expertise and interstate commerce in medicine override state-level abortion policy. The case sits at the intersection of administrative law, constitutional federalism, and modern abortion access strategy.